Albendazole for the treatment of human gnathostomiasis.
The efficacy of albendazole was investigated in 112 patients with symptomatic gnathostomiasis; 49 received 400 mg twice daily, 51 received 400 mg once daily, and 12 patients received placebo, all for 21 d. Subsequent follow-up was for 6 months. Cure (no further swelling) was seen in 93.9% and 94.1% of the treatment groups but in none of the placebo group. Additionally, reductions in eosinophil counts and in immunoglobulin G antibody were observed after treatment. Side effects were minimal. Albendazole may be an effective compound for the treatment of gnathostomiasis.
Kraivichian
P
P
Department of Parasitology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Kulkumthorn
M
M
Yingyourd
P
P
Akarabovorn
P
P
Paireepai
C C
CC
D000293:Adolescent; D000328:Adult; D000368:Aged; D015766:Albendazole / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000977:Antiparasitic Agents; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006039:Gnathostoma / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009349:Nematode Infections / Q000188:drug therapy* / Q000469:parasitology; D012008:Recurrence; D012867:Skin / Q000469:parasitology; D016896:Treatment Outcome
D000977:Antiparasitic Agents; D015766:Albendazole